Emergent Biosolutions Ownership
| EBS Stock | USD 10.89 1.08 9.02% |
Shares in Circulation | First Issued 2004-03-31 | Previous Quarter 52.6 M | Current Value 55.6 M | Avarage Shares Outstanding 40.4 M | Quarterly Volatility 11.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Emergent |
Emergent Stock Ownership Analysis
About 57.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Emergent Biosolutions has Price/Earnings To Growth (PEG) ratio of 1.55. The entity recorded a loss per share of 11.22. The firm had not issued any dividends in recent years. Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people. To learn more about Emergent Biosolutions call Joseph Papa at 240 631 3200 or check out https://www.emergentbiosolutions.com.Besides selling stocks to institutional investors, Emergent Biosolutions also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Emergent Biosolutions' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Emergent Biosolutions' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Emergent Biosolutions Quarterly Liabilities And Stockholders Equity |
|
Emergent Biosolutions Insider Trades History
Roughly 2.0% of Emergent Biosolutions are currently held by insiders. Unlike Emergent Biosolutions' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Emergent Biosolutions' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Emergent Biosolutions' insider trades
Emergent Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Emergent Biosolutions is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Emergent Biosolutions backward and forwards among themselves. Emergent Biosolutions' institutional investor refers to the entity that pools money to purchase Emergent Biosolutions' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-06-30 | 649.5 K | Goldman Sachs Group Inc | 2024-06-30 | 611 K | Two Sigma Advisers, Llc | 2024-06-30 | 575.4 K | Geode Capital Management, Llc | 2024-06-30 | 556.2 K | Bank Of America Corp | 2024-06-30 | 554.9 K | Carronade Capital Management Lp | 2024-06-30 | 550.6 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 542.8 K | Jane Street Group Llc | 2024-06-30 | 490.8 K | Aqr Capital Management Llc | 2024-06-30 | 460.3 K | Blackrock Inc | 2024-06-30 | 3.8 M | Vanguard Group Inc | 2024-06-30 | 3.7 M |
Emergent Biosolutions Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Emergent Biosolutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on Emergent Biosolutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Emergent Biosolutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Emergent Biosolutions Outstanding Bonds
Emergent Biosolutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Emergent Biosolutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Emergent bonds can be classified according to their maturity, which is the date when Emergent Biosolutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| EMBRAER NETH FIN Corp BondUS29082HAB87 | View | |
| EMERGENT BIOSOLUTIONS INC Corp BondUS29089QAC96 | View | |
| US29082KAA34 Corp BondUS29082KAA34 | View | |
| EMERA INC 675 Corp BondUS290876AD37 | View |
Emergent Biosolutions Corporate Filings
S1 | 12th of November 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.